Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial

Kensei Tobinai, MD, PhD¹

¹National Cancer Center Hospital, Tokyo, Japan; ²Department of Hematology, Saitama, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ³Department of Hematology, Saitama, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ⁵Daiichi Sankyo Co., Ltd., ¹Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ¹Nagoya, Sciences, Nagoya, Sciences, Nagoya, Sciences, Sciences, Nagoya, Sciences, Sc Tokyo, Japan; ⁶Daiichi Sankyo Inc., Basking Ridge, NJ, US

PURPOSE

- To describe the safety and tolerability of valemetostat tosylate (valemetostat) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) and T-cell NHLs (T-NHLs) enrolled in the DS3201-A-J101 ("J101"; NCT02732275) trial
- To report primary clinical outcomes for the subgroup of patients with R/R B-NHLs, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

CONCLUSIONS


- Valemetostat monotherapy demonstrated encouraging preliminary clinical activity with durable responses (duration of response [DOR] > 1.5 years) in patients with R/R B-NHLs
- The safety profile of valemetostat was acceptable; cytopenias were common but manageable and did not require treatment discontinuation
- Results for patients in this trial with R/R T-NHLs are described in an abstract by Jacobsen et al. (abstract #303) at this congress
- Ongoing trials of valemetostat monotherapy in patients with R/R B-NHLs include a phase 2 trial in France and Belgium (NCT04842877) and a phase 1/2 trial of valemetostat plus rituximab and lenalidomide (R²) in the US (NCT05683171)



Copies of this poster obtained through Quick Response (QR) Code or https://bit.ly/DSIASH2023 are for personal use only and may not be reproduced without permission from the author of this material

BACKGROUND

- B-NHLs, including DLBCL and FL, are among the most common NHLs
- Enhancer of zeste homolog (EZH)2 and its close homolog EZH1 catalyze the trimethylation of histone H3 at lysine 27 (H3K27me3), leading to transcriptional repression^{1,2}
- EZH2 is involved in mediating B-cell development, and many NHLs are correlated with EZH2 dysregulation^{3,4}
- EZH2 gain-of-function (GOF) mutations at tyrosine 641 are known to occur in germinal center B-cell–like DLBCL and FL; one study estimated the occurrence of this mutation to be 22% and 7%, respectively, and other studies have indicated that it may be more common^{5,6}
- Preclinical models suggest that EZH1 compensates for the loss of EZH2 in lymphoma cells^{7,8}
- Valemetostat is a novel, potent, and selective dual inhibitor of EZH2 and EZH1 (Figure 1) approved in Japan for the treatment of R/R adult T-cell leukemia/lymphoma (ATLL)^{9,10}
- J101 is a multicenter, open-label, single-arm, phase 1 trial of valemetostat in patients with R/R B-NHLs and T-NHLs



METHODS

Study design

- (Figure 2)

Efficacy analysis

2007 response criteria

Pharmacokinetic (PK) analysis

plasma PK of valemetostat

Pharmacodynamic analysis

version 1

Figure 2. Study design, key inclusion criteria, and endpoints of the J101 trial

Key inclusion crit • R/R B- or T-NHL • ≥ 1 prior line of ther • Aged ≥ 20 (Japan) • ECOG PS score 0
 Primary endpoint Safety (including D RP2D PK parameters
Secondary endpo • Safety • Efficacy
Safety

^aNumber includes the 1 patient excluded from all analyses due to a good clinical practice (GCP) violation; ^bNumber excludes 2 patients without measurable lesions at baseline. DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; PO, by mouth; PTCL, peripheral T-cell lymphoma; RDE, recommended dose for expansion; RP2D, recommended phase 2 dose; TEAE, treatment-emergent adverse event.

RESULTS

Patient characteristics

- Overall, the trial enrolled 91 patients with R/R NHLs
- One patient was excluded from analysis sets due to a GCP violation • The primary trial cutoff occurred on Dec 31, 2022
- Nineteen patients with R/R B-NHLs were enrolled in Part 1 (dose escalation) of the trial and had received \geq 1 dose of valemetostat, including 7 patients with DLBCL, 7 with FL, 3 with indolent B-NHL, and 2 with other B-NHLs (Table 1) - Median number of prior therapies was 2 (range 0–6), and no patient in this cohort had received prior hematopoietic cell transplantation (HCT)

Disposition

- As of the primary trial cutoff, study treatment was ongoing in 2 (11%) patients with B-NHLs and had been discontinued in 17 (89%) patients
- Reasons for discontinuation included progressive disease (PD; 8 [42%] patients), clinical progression (2 [11%]), adverse events (1 [5%]), physician decision (1 [5%]), and withdrawal by patient (5 [26%])

Koji Izutsu, MD, PhD,¹ Kenji Ishitsuka, MD, PhD,² Dai Maruyama, MD, PhD,³ Shigeru Kusumoto, MD, PhD,³ Shinji Tsutsumi, PhD,⁶ Masaya Tachibana, PhD,⁵ Shinji Tsutsumi, PhD,⁶ Masaya Tachibana, PhD,⁶ Masaya Tachibana, PhD,⁵ Shinji Tsutsumi, PhD,⁶ Masaya Tachibana, PhD,⁶ Masaya T


• Adult patients eligible for participation in the J101 trial had confirmed B- or T-NHL as defined by the World Health Organization 2016 classification criteria and had relapsed from, were refractory to, or ineligible for standard therapies The trial included a dose-escalation part followed by a dose-expansion part

• Patients with a histological diagnosis of B- or T-NHL were enrolled in the dose-escalation part and received valemetostat once daily (QD) at doses of 150–300 mg in continuous 28-day treatment cycles

 Efficacy assessments included objective response rate (ORR), complete response (CR) rate, and DOR based on the International Working Group (IWG)

• Serial blood samples were collected on days 1 and 15 of cycle 1 to assess

• Gene mutation analysis was performed on DNA samples collected at baseline in a subset of patients with B-NHLs by next-generation sequencing using the Oncomine[™] Comprehensive Assay (Thermo Fisher Scientific; Waltham, MA),



Characteristic	B-NHL (n = 19)	T-NHL (n = 71)	Total (N = 90)
Age (years), median (range)	66.0 (44–88)	68.0 (26–83)	67.5 (26–88)
Sex, n (%)			
Male	10 (53)	43 (61)	53 (59)
Female	9 (47)	28 (39)	37 (41)
Country of enrollment, n (%)			
US	0	44 (62)	44 (49)
Japan	19 (100)	27 (38)	46 (51)
ECOG PS score, n (%)			
0	15 (79)	29 (41)	44 (49)
1	4 (21)	41 (58)	45 (50)
≥ 2ª	0	1 (1)	1 (1)
Cancer type, n (%)			
B-NHL	19 (100)	0	19 (21)
DLBCL	7 (37)	0	7 (8)
FL	7 (37)	0	7 (8)
Indolent B-cell lymphoma excluding FL	3 (16)	0	3 (3)
Mantle cell lymphoma	1 (5)	0	1 (1)
LPL	1 (5)	0	1 (1)
T-NHL	0	71 (100)	71 (79)
PTCL	0	57 (80)	57 (63)
ALCL	0	2 (3)	2 (2)
AITL	0	23 (32)	23 (26)
PTCL, NOS	0	26 (37)	26 (29)
Other T-cell lymphoma	0	6 (8)	6 (7)
ATLL	0	14 (20)	14 (16)
EZH2 GOF mutation, n (%)	1 (11) ^b	Oc	1 (2) ^d
Prior lines of therapy, median (range)	2 (0–6)	2 (1–8)	2 (0–8)
Prior HCT, n (%)	0	18 (25)	18 (20)
Assigned valemetostat dose, n (%)			
150 mg/day	3 (16)	4 (6)	7 (8)
200 mg/day	7 (37)	67 (94)	74 (82)
250 mg/day	7 (37)	0	7 (8)
300 mg/day	2 (11)	0	2 (2)

COG PS score of 4 was eligible for the study at the time of screening; ^bEZH2 mutation status assessed in 9 patient AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; LPL, lymphoplasmacytic lymphoma; NOS, not otherwise specified.

Efficacy in B-NHL

- The ORR in patients with R/R B-NHL was 47% (9/19; 95% confidence interval [CI], 24.4–71.1)
- Clinical responses were observed in 3/7 patients with DLBCL and 4/7
- this patient achieved a partial response (PR)
- Treatment duration and clinical response for individual patients is shown in Figure 3
- Of 19 patients, 9 (47%) achieved reductions of \geq 50% from baseline in the sum of target lesion areas during valemetostat treatment (Figure 4)

Safety and tolerability

• All 90 patients with B-NHLs or T-NHLs experienced at least 1 TEAE, including 78 (87%) who had treatment-related TEAEs

Table 2. Clinical responses in patients with R/R B-NHLs

Response	All B-NHL (N = 19)
Best overall response, n (%)	
CR	2 (11)
PR	7 (37)
SD	8 (42)
PD	2 (11)
ORR,ª % (n/N)	47 (9/19)
[95% CI] ^b	[24.4, 71.1]
Time to response, median, months	3.7
(Range)	(1.9–10.1)
DOR, ^c median, months	18.4
[95% CI] ^b	[5.3, NR]
Follow-up time, ^d median, months	49.2
[95% CI] ^e	[0.03, 64.0]
Clinical response defined per IWG 2007 response criteria. ORR was the pro	

on Clopper–Pearson method; ^cMedian DOR was estimated using Kaplan–Meier methods; ^cMedian follow-up time was estimated using reverse Kaplan-Meier methods; eCI was computed using Brookmeyer—Crowley method. NR, not reached; SD, stable disease,

patients with FL; 1 patient in each of these groups achieved CR (Table 2) An EZH2 GOF mutation was identified in 1/5 evaluable patients with FL

NMZL · EMZL –

Figure 3. Exposure duration and best clinical responses





Figure 4. Percent change from baseline in target lesion areas



- The most common TEAEs (any grade) were decreased platelet count (64%). dysgeusia (50%), anemia (43%), decreased neutrophil count (34%), and alopecia (33%; **Table 3**)
- The most common grade \geq 3 TEAEs were cytopenias, including decreased neutrophil count (24%), platelet count (24%), and lymphocyte count (19%; Table 4)
- Treatment-emergent serious adverse events (SAEs) occurred in 39 (43%) patients; 32 (36%) patients had SAEs of \geq grade 3
- TEAEs required treatment discontinuation for 7 (8%) patients, dose reduction for 9 (10%) patients, and treatment interruption for 42 (47%) patients
- Maximum tolerated dose was not reached between 150 and 300 mg/day based on the modified continual reassessment method (mCRM). RP2D/RDE was determined to be 200 mg/day based on the mCRM, safety findings, preliminarily efficacy, and PK/pharmacodynamic analyses

Table 3. TEAEs (all grades) that occurred in ≥ 15% of patients with NHLs

	Valemetostat dose				
Preferred term, n (%)	150 mg/day (n = 7)	200 mg/day (n = 74)	250 mg/day (n = 7)	300 mg/day (n = 2)	All dose levels (N = 90)
Platelet count decreased ^a	5 (71)	44 (59)	7 (100)	2 (100)	58 (64)
Dysgeusia	4 (57)	34 (46)	6 (86)	1 (50)	45 (50)
Anemia ^b	3 (43)	31 (42)	3 (43)	2 (100)	39 (43)
Neutrophil count decreased ^c	2 (29)	24 (32)	3 (43)	2 (100)	31 (34)
Alopecia	3 (43)	23 (31)	4 (57)	0	30 (33)
White blood cell count decreased ^d	1 (14)	20 (27)	4 (57)	2 (100)	27 (30)
Diarrhea	2 (29)	20 (27)	4 (57)	0	26 (29)
Lymphocyte count decreased ^e	3 (43)	12 (16)	6 (86)	2 (100)	23 (26)
Nausea	2 (29)	18 (24)	1 (14)	0	21 (23)
Fatigue	2 (29)	14 (19)	2 (29)	0	18 (20)
Alanine aminotransferase increased	2 (29)	13 (18)	2 (29)	0	17 (19)
Aspartate aminotransferase increased	1 (14)	13 (18)	1 (14)	0	15 (17)
Pyrexia	0	13 (18)	2 (29)	0	15 (17)
Decreased appetite	2 (29)	13 (18)	0	0	15 (17)
Cough	0	14 (19)	0	0	14 (16)
^a Platelet count decreased includes Medical Dictionary for Regulatory Activities (MedDRA) preferred terms Thrombocytopenia and Platelet count decreased; ^b Anemia includes Anemia, Hemoglobin decreased, and Red blood cell count decreased; ^c Neutrophil count decreased includes Neutropenia and Neutrophil count decreased; ^d White blood cell count decreased includes Leukopenia and White blood cell count decreased; ^e Leukopenia and blood cell count decreased; ^e Leukope					

blood cell count decreased; ^eLymphocyte count decreased includes Lymphopenia and Lymphocyte count decreased; ^fFatigue includes Asthenia and Fatigue.



→ Treatment continuation

Table 4. TEAEs (grade \geq 3) that occurred in \geq 3 patients with NHLs


	Valemetostat dose				
Preferred term, n (%)	150 mg/day (n = 7)	200 mg/day (n = 74)	250 mg/day (n = 7)	300 mg/day (n = 2)	All dose levels (N = 90)
Neutrophil count decreased ^a	0	18 (24)	2 (29)	2 (100)	22 (24)
Platelet count decreased ^b	2 (29)	17 (23)	1 (14)	2 (100)	22 (24)
Lymphocyte count decreased ^c	2 (29)	10 (14)	5 (71)	0	17 (19)
Anemiad	2 (29)	11 (15)	1 (14)	1 (50)	15 (17)
White blood cell count decreased ^e	1 (14)	10 (14)	1 (14)	1 (50)	13 (14)
Gamma-glutamyltransferase increased	1 (14)	4 (5)	1 (14)	0	6 (7)
Hypertension	0	5 (7)	0	0	5 (6)

decreased; ^cLymphocyte count decreased includes Lymphopenia and decreased, and Red blood cell count decreased; "White blood ce ncludes Leukopenia and White blood cell count decreased

PK

- PK parameters and the concentration-time profile of valemetostat 200 mg/day are presented in Figure 5
- Valemetostat showed variability in exposure between patients
- Peak valemetostat plasma concentration occurred at a median time to reach maximum plasma concentration (Tmax) of approximately 4 hours
- Accumulation of valemetostat plasma exposure was minimal

Figure 5. PK parameters and time course of mean plasma valemetostat concentrations on C1D1 and C1D15 at 200 mg/day in patients with NHLs




ªn = 74; ⁵n = 66; °n = 65; ₫n = 58

ax and AUCtau values in table represent mean (standard deviation [SD]); Tmax value in table represents median (minimum mum). Data points in graph represent mean ± SD UCtau, area under the plasma concentration-time curve during the dosing interval; C1D1, cycle 1 day 1; C1D15, cycle 1 day 15; Cmax naximum plasma concentratio

Gene mutations in patients with **B-NHLs**

• Among 9 patients with available data, GOF mutations were identified in 3 patients and loss-of-function mutations in 2 patients (Figure 6)

Figure 6. Gene mutations identified in patients with B-NHLs



Gene mutation analysis was performed on DNA samples collected at baseline in a subset of patients (n = 9) with B-NHLs LOF, loss-of-function.

REFERENCES

- 1. Herviou L, et al. Oncotarget 2016;7:2284.
- 2. Nakagawa M, Kitabayashi I. Cancer Sci 2018;109:2342-2348.
- 3. Shi M, et al. Leuk Lymphoma 2015;56:2087–2091
- 4. Fujikawa D, et al. *Blood* 2016;127:1790–1802. 5. Morin RD, et al. Nat Genet 2010;42:181–185.
- **ACKNOWLEDGMENTS**
- 6. Bödör C, et al. Blood 2013;122:3165-3168.
- 7. Shen X, et al. Mol Cell 2008;32:491–502. 8. Yamagishi M, et al. Cell Rep 2019;29:2321-2337.
- 9. Keam SJ. Drugs 2022;82:1621–1627.
- 10. EZHARMIA[®] (valemetostat tosilate). [package insert] Tokyo, Japan: Daiichi Sankyo; 2022.
- The authors thank the patients, families, and caregivers for their participation, and the study staff for their contributions This study is sponsored by Daiichi Sankyo Co., Ltd
- Editorial support was provided by Luca Scrivano and Korin Albert of Excerpta Medica, funded by Daiichi Sankyo Co., Ltd., in accordance with Good Publication Practice guidelines